UNC Libraries
Changes in cardiometabolic biomarkers 1 year after direct acting antiviral therapy for hepatitis C virus co‐infection among people with HIV
By Leila H. Borowsky, Jennifer O. Lam, North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS and 14 others.
Abstract
Objectives
Among people with HIV with hepatitis C virus (HCV) co-infection, we examined differences in haemoglobin A1c (HbA1c), total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL) and atherosclerotic cardiovascular disease (ASCVD) risk score at 12-months following direct acting antiviral (DAA) initiation, comparing people with HIV who initiated DAA with those who did not to explore the utility of DAAs beyond HCV elimination.
Methods
Utilizing a nested exposure-matched study of people with HIV age ≥ 18 years, on antiretroviral therapy from the NA-ACCORD and the Mass General Brigham HIV cohorts between 01/1/2014 and 12/31/2022, people with HIV with HCV co-infection were identified by detectable plasma HCV RNA. People with HIV who initiated DAA were matched 1:1 with people with HIV who did not initiate DAA. Multivariable linear regression models estimated HbA1c (N = 2374), TC (N = 3418) and ASCVD risk score (N = 488) at 12-months comparing people with HIV who initiated DAAs versus did not.